🇺🇸 FDA
Pipeline program

Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

2024-0013-RCOC

Approved small_molecule active

Quick answer

Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) for Diabetic Macular Edema (DME) is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Diabetic Macular Edema (DME)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials